TECHWIRE 30
(CIX: WRAL30)  981.51    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Apple)  517.96    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: QUINTILES)  50.67    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: BASF SE)  106.59    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: BioCryst)  8.33    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: BioDelivery)  7.13    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: CEMP)  8.73    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Cisco Systems)  22.89    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  55.51    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: DARA)  2.50    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: EMC CORPORATION)  26.92    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Extreme Networks)  5.65    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Facebook)  59.09    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: GLAXOSMITHKLINE)  52.32    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: GOOG)  536.44    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: IBM)  197.02    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NY: LH)  101.56    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: Lenovo Group)  23.40    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: MRK)  56.05    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Microsoft Corp)  39.75    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: NetApp)  37.00    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: NOVARTIS AG)  83.79    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: Novozymes A/S)  43.66    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: PFIZER)  29.89    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Pozen)  8.47    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: RED HAT)  50.10    (0 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: BBRY)  7.21    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Salix)  98.19    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: SQI)  25.03    (0 %)  Updated: 08:10 PM EDT, Apr 15 2014

Posts tagged “GSK”

Updated 5:50 a.m. yesterday

Bribery investigations continue to surface for Glaxo

The BBC is reporting that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland, making this the third country to have an investigation currently ongoing.

GSK's HQ in London     GSK's HQ in London

April 8

GSK launches probe into Iraq bribery claims

GSK's HQ in London     Drug giant GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China.

Updated March 5

Premium Lock GSK, J&J preparing to test once-a-month AIDS medicines

HIV research GlaxoSmithKline and Johnson & Johnson are preparing to test the first monthly injections of experimental AIDS drugs in a study that may transform the treatment of the deadly disease.

Updated February 27

Premium Lock GSK cuts CEO's bonus some 12 percent due to China scandal

Andrew Witty  "Both Sir Andrew and the board are mindful of the impact this issue has had on the reputation of the company," GSK's chairman says. "As a result, the bonuses awarded for 2013 were lower than they otherwise might have been."

February 26

Premium Lock Novartis joins GSK, Sanofi in opening some drug trial data to researchers

Drug research Novartis will join companies such as GlaxoSmithKline and Sanofi in allowing researchers access to clinical trial data, as regulators demand more transparency.

February 21

Premium Lock GSK lung drug Anoro recommended for European approval

Lung disease Anoro may help GSK protect its respiratory business, which made up 42 percent of its total pharmaceutical sales last year. The company's top-selling product, Advair for smokers' cough and asthma, is facing increasing competition from a newly approved generic in Europe and cheaper options in the U.S.

February 4

Premium Lock GSK, others team with NIH in $230M effort to fight Alzheimer's, other diseases

Alzheimer's Data generated from the work will be made public for other scientists to use, a move that the U.S. National Institutes of Health called groundbreaking. The targeted diseases are some of the most prevalent conditions among Americans, costing the nation billions of dollars in treatment and lost productivity.

Updated January 31

Premium Lock 239,000 STEM jobs beckon in N.C., but report says state not delivering enough qualified students

The warning is stark: "The danger we face today is the possibility that fewer people will enter highly technical fields in the decades ahead, at a time when demand for individuals with these kinds of skills is on the rise." U.S. student achievement in STEM fields lags many industrialized countries, and North Carolina students lag many states. But pharma companies are stepping in to help bridge the gap. WRALTechWire examines the report from Battelle and its implications for North Carolina as well as the U.S.

STEM acheivement in science STEM acheivement in science

Updated January 22

Premium Lock RTI partners on epilepsy work; SAS ranked in report; lawyers use cloud tools; Kenan-Flagler dean recommended; Abbott gets new trial

Bulldog In our Bulldog Blog's latest life sciences and technology update: RTI partners on epilepsy network; SAS makes ranking; lawyers use more cloud tools; Kenan-Flagler dean recommended; AbbVie gets new drug trial.

Updated January 22

Premium Lock GSK's joint venture HIV drug wins approval in Europe

HIV research A ViiV Healthcare combination HIV drug has received regulatory approval from the European Commission, GlaxoSmithKline says. ViiV is seeking approval for the drug in the U.S. as well.

January 15

Premium Lock GSK: China sales improving after 61% drop; CDC affirms rotavirus vaccine

GSK China GlaxoSmithKline says sales in China, where the company faces a bribery probe, have improved since the third quarter when revenue plunged 61 percent from a year earlier. In other news, the CDC affirmed support for rotavirus vaccines that combat severe diarrhea in infants from GSK and Merck.

January 13

Premium Lock GSK lands 'breakthrough' FDA designation for lung cancer treatment

GSK's HQ in London     Good news, bad news for GlaxoSmithKline on Monday: A treatment for metastatic lung cancer receives "Breakthrough Therapy" designation from the FDA. However, GSK also says it has dropped development of a muscular dystrophy treatment.

Tags: GSK
January 9

Premium Lock GSK wins 'accelerated approval' for combination cancer treatment targeting melanoma

Cancer research In what GlaxoSmithKline says is a first, the drug giant has received FDA approval for a combination of its cancer drugs that target a form of melanoma linked to specific genetic mutations.

December 30, 2013

Premium Lock GSK could wind up on China bribery blacklist

GSK China GlaxoSmithKline could find itself on a new blacklist in China blocking pharmaceutical companies and medical device manufacturers implicated in bribery from selling their products.

December 19, 2013

Premium Lock On ending pharma payments to docs, GSK stands alone

Doctors prefer to learn about treatment options from their peers, and payments make sense given the time and energy required to understand and share information, according to companies that plan to keep remunerating physicians.

Andrew Witty  Andrew Witty

December 19, 2013

Premium Lock GSK adds Duke in biolectric collaboration, announces $1M bioelectronics prize

GSK envisions a day when tiny implantable devices take the place of pills or injections. The pharma giant is collaborating with universities and encouraging research in bioelectronics, the use of electricity in therapeutic applications.

Click here to open the YouTube video in a new window.

December 18, 2013

Premium Lock COPD drug from GSK, Theravance gets FDA approval

GlaxoSmithKline and Theravance received FDA approval on Anoro Ellipta, a drug indicated for treating chronic obstructive pulmonary disease (COPD). Read more about the drug and GSK's launch plans.

Lung disease Lung disease

Updated December 17, 2013

Premium Lock GSK to end doctor payments, will alter sales force compensation

Drug giant GlaxoSmithKline, which is mired in a bribery scandal in China, says it is ending payments to doctors for promoting their products. The company also is changing its sales force compensation plan to reflect one implemented for its U.S. sales people in 2011.

GSK's HQ in London     GSK's HQ in London

Updated December 16, 2013

Premium Lock GSK to invest $1B in India, some $350M in U.K. expansions

GSK Headquarters     Global drug giant GlaxoSmithKline is expanding its presence in India and in the U.K. with investments totaling some $1.35 billion. The home-country growth comes in the wake of the U.K.'s recently overhauled patent system.

December 9, 2013

Premium Lock GSK research paper based on work in China is retracted

GSK China GSK recommended withdrawing the article, published in 2010, after concluding an investigation in June that found some data had been misrepresented, London-based Glaxo said in a statement Friday. Five of the named authors, including the head of its Chinese research and development, resigned or were fired following the probe.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll